Exact Sciences Corporation (EXAS)
| Market Cap | 20.91B |
| Revenue (ttm) | 1.55B |
| Net Income (ttm) | -774.00M |
| Shares Out | 169.43M |
| EPS (ttm) | -4.76 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 11 |
| Last Price | $121.89 |
| Previous Close | $121.91 |
| Change ($) | -0.02 |
| Change (%) | -0.02% |
| Day's Open | 122.00 |
| Day's Range | 119.88 - 124.49 |
| Day's Volume | 1,598,788 |
| 52-Week Range | 70.75 - 159.54 |
Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock?
Investors are optimistic about Exact Sciences (EXAS) on solid first-quarter performance and strategic partnerships.
Modeling data exhibits efficacy of Exact Sciences' (EXAS) Cologuard compared to FIT and other colorectal cancer diagnostic options.
They're well below peak levels set earlier this year. But they could be huge winners over the long run.
MADISON, Wis., May 24, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following virtual conferences and invited investors to par...
MADISON, Wis., May 21, 2021 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today highlights data from one oral and one poster presentation being featured at the 2021 Digestive Disease Week® (DDW®) ...
Exact Sciences (EXAS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more streng...
The company's Cologuard DNA test appears to be in good shape to maintain its market leadership.
MADISON, Wis., May 19, 2021 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a global leader in cancer diagnostics, today announced new data on its cancer tests and treatment guidance tools will be ...
Buying the stock market weakness? Or staying on the sidelines?
MADISON, Wis., May 18, 2021 /PRNewswire/ -- The United States Preventive Services Task Force (USPSTF) today released its final colorectal cancer screening recommendation that screening begin at age 45.
Despite ongoing pandemic-related headwinds, the medical diagnostic test maker's revenue grew. So how will it perform as those headwinds dissipate?
The company has other more significant growth drivers.
Falling costs are ushering in a new era of screening for a dreaded disease.
CareDx just posted 76% year-over-year revenue growth for the first quarter and raised its 2021 guidance.
Exact Sciences' (EXAS) first-quarter 2021 revenues improved year over year led by growth in Precision Oncology, COVID-19 testing and Screening revenues.
There was a big asterisk with the company's improved bottom line.
Exact Sciences (EXAS) delivered earnings and revenue surprises of 82.69% and 4.50%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
MADISON, Wis., May 4, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $402.1 million for the first quarter ended March 31, 2021, compared t...
MADISON, Wis., May 3, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following conferences and invited investors to participate ...
Cologuard® CRC Screening Test Most Cost-Effective Test in Medically Underserved Alaska Native People
MADISON, Wis., April 28, 2021 /PRNewswire/ -- Exact Sciences (NASDAQ: EXAS) today announces study results published in Mayo Clinic Proceedings showing that Cologuard (mt-sDNA) is the most cost-effective...
These three stocks have just one thing in common: The potential for explosive growth.
Digital wallets and genomics will transform the world in coming years.
MADISON, Wis., April 14, 2021 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced that it has completed its previously announced acquisition of Ashion Analytics, LLC.
MADISON, Wis., April 8, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company plans to release its first quarter 2021 financial results after the close of the U.S. fi...
Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock?
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Ark Funds hosted an investor webinar Tuesday, sharing ideas on several industries and portfolio components, including a discussion on some names in the genomics space. Ark Funds On Genomics: Ark Funds i...
MADISON, Wis., Feb. 22, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following virtual conferences and invited investors to pa...
These two companies have exciting long-term prospects.
The company reported disappointing Q4 results.
Exact Sciences' (EXAS) legacy Screening business sees an uptick in revenues in Q4 earnings.
Due to an accounting charge taken because of an acquisition, the company was deep in the red on the bottom line.
Shares of Exact Sciences (NASDAQ:EXAS) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 59.46% over the past year to ($0.15), which beat the ...
MADISON, Wis., Feb. 16, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $466.3 million for the fourth quarter ended Dec. 31, 2020 and $1,49...
MADISON, Wis., Feb. 16, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has entered into an agreement to acquire Ashion Analytics, LLC (Ashion) from The Translational Ge...
Exact Sciences (NASDAQ:EXAS) announces its next round of earnings this Tuesday, February 16. Here is Benzinga's look at Exact Sciences's Q4 earnings report.
Exact Sciences (EXAS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength in Precision Oncology business is likely to have continued to aid Exact Sciences' (EXAS) performance in the fourth quarter of 2020 amid the coronavirus-led economic doldrums.
MADISON, Wis., Feb. 1, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following conferences and invited investors to participate...
MADISON, Wis., Feb. 1, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company plans to release its fourth quarter 2020 financial results after the close of the U.S. fi...
Stock Indexes Hold Tough, But Leaders Struggle: Datadog, Exact Sciences, Freeport McMoRan In Focus
Stock indexes hold tough, but leaders struggle: Datadog, Exact Sciences, Freeport McMoRan in focus. Investor's Business Daily has been helping people invest smarter results by providing exclusive stock ...
Multi-cancer screening is the holy grail for the test industry. Exact Sciences is pursuing it by acquiring complementary companies.
Exact Sciences' (EXAS) strength in Screening revenue along with a robust COVID-19 testing arm are likely to have boosted the top line significantly.
MADISON, Wis., Jan. 12, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) announced data published today in Cancer Prevention Research, a Journal of the American Association for Cancer Research, ...
About EXAS
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype MAP, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX ... [Read more...]
| Industry Diagnostics & Research | Founded 1995 |
| CEO Kevin Conroy | Employees 4,800 |
| Stock Exchange NASDAQ | Ticker Symbol EXAS |
Financial Performance
In 2020, Exact Sciences's revenue was $1.49 billion, an increase of 70.19% compared to the previous year's $876.29 million. Losses were -$848.53 million, 910.2% more than in 2019.
Analyst Forecasts
According to 16 analysts, the average rating for Exact Sciences stock is "Strong Buy." The 12-month stock price forecast is 156.89, which is an increase of 28.71% from the latest price.